{"id":"ibandronate-bonviva-boniva","safety":{"commonSideEffects":[{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Atypical femoral fracture (rare)"},{"rate":null,"effect":"Osteonecrosis of the jaw (rare)"}]},"_chembl":{"chemblId":"CHEMBL3989569","moleculeType":"Small molecule","molecularWeight":"359.23"},"_fixedAt":"2026-03-30T13:23:00.714217","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bisphosphonates like ibandronate are taken up by osteoclasts during bone resorption and inhibit farnesyl pyrophosphate synthase, disrupting the prenylation of small GTPases required for osteoclast function and survival. This leads to decreased bone turnover and increased bone mineral density, making it effective for conditions characterized by excessive bone loss.","oneSentence":"Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking the mevalonate pathway in osteoclasts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:53.853Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Bone metastases in breast cancer"},{"name":"Hypercalcemia of malignancy"}]},"_fixedFields":["pubmed(1193)"],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1193,"recentPublications":[{"date":"2026 Feb 23","pmid":"41725388","title":"Expected change: a new concept for monitoring patients on oral bisphosphonates.","journal":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"date":"2026 Feb 26","pmid":"41661180","title":"A novel approach for discriminating lipophilic bisphosphonate-based pharmaceuticals using a potentiometric array.","journal":"Analytical methods : advancing methods and applications"},{"date":"2026 Jan 15","pmid":"41578815","title":"Evaluation of Osteonecrosis Risk Using Serum C-Terminal Cross-Linked Telopeptide of Type 1 Collagen (CTX-1) Levels in Osteoporotic Patients: Effects of Drug Holidays and Risk Factors.","journal":"The Eurasian journal of medicine"},{"date":"2025","pmid":"41568387","title":"Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis.","journal":"Frontiers in oncology"},{"date":"2026 Jan 12","pmid":"41524786","title":"Post-fracture care and predictors of anti-osteoporotic treatment in Switzerland: a nationwide health claims analysis.","journal":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ibandronate [Bonviva/Boniva]","genericName":"ibandronate [Bonviva/Boniva]","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking the mevalonate pathway in osteoclasts. Used for Osteoporosis in postmenopausal women, Bone metastases in breast cancer, Hypercalcemia of malignancy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}